TScan Therapeutics Q4 EPS $(0.21) Beats $(0.29) Estimate, Sales $7.21M Beat $3.34M Estimate, Cash Balance of $192.0M to Fund its Current Operating Plan into 2026
Author: Benzinga Newsdesk | March 06, 2024 08:08am
TScan Therapeutics (NASDAQ:
TCRX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.29) by 27.59 percent. This is a 73.08 percent increase over losses of $(0.78) per share from the same period last year. The company reported quarterly sales of $7.21 million which beat the analyst consensus estimate of $3.34 million by 115.90 percent. This is a 132.91 percent increase over sales of $3.10 million the same period last year.
Posted In: TCRX